FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.